Physician profile
Katy E Crowe
NPI 1962662122
$12,230.81
in general payments reported to CMS, 2019-2025
58 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,573 · 2021: $2,078 · 2022: $1,970 · 2023: $1,940 · 2024: $1,668 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,680.29 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Abbvie INC. | $1,596.56 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,097.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $855.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $764.53 | 2019-2025 | |
| Astellas Pharma US INC | $651.19 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $635.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $544.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $359.58 | 2019-2023 | Livalo, Seglentis |
| Abbott Laboratories | $356.00 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $340.02 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Teva Pharmaceuticals USA, INC. | $320.88 | 2019-2023 | Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.29 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $274.23 | 2024-2025 | Orladeyo |
| Janssen Pharmaceuticals, INC | $209.73 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.